To achieve efficient inhibitor management it is crucial to ensure the highest quality of multidisciplinary treatment and care. Also, the following aspects – awareness, diagnosis, prevention of bleeds by bypassing agents and systematic immune tolerance induction (ITI) in all patients including adults – should be taken into account. To facilitate inhibitor management and seek the same quality of treatment and care for all inhibitor patients, regardless of the haemophilia treatment centre (HTC) or country, the European Principles of Inhibitor Management (EPIM) have been developed by a team of multidisciplinary treatment and care experts from across Europe.
European Principles of Inhibitor Management (EPIM)
The article was published in the scientific journal Orphanet Journal of Rare Diseases (OJRD) in April 2018 and can be accessed here.
Following the advent of novel treatment options for people with inhibitors, the revised version of the article was published in OJRD in August 2020 and can be accessed here.
An infographic summarising the principles can be accessed here.
